Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kirsten Bell-Burdett"'
Autor:
Alfredo Falcone, Chiara Cremolini, Jing Lyu, Dominic T. Moore, Daniele Rossini, Richard M. Goldberg, Anastasia Ivanova, Yingmiao Liu, Ace J. Hatch, Alexander B. Sibley, Kelli Hammond, Andrew B. Nixon, Federica Marmorino, Federico Innocenti, Hanna K. Sanoff, Mark D. Starr, Kouros Owzar, John C. Brady, Kirsten Bell Burdett, Michael S. Lee
Publikováno v:
Molecular Cancer Therapeutics. 19:2146-2154
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Autor:
Heather A. Lankes, Michael J. Birrer, Robert A. Burger, Yingmiao Liu, David M. O'Malley, Matthew P. Boente, Wei Deng, Andrew B. Nixon, Jamie N. Bakkum-Gamez, J. Chris Brady, Kouros Owzar, Krishnansu S. Tewari, Kirsten Bell Burdett, David Tritchler, Mark D. Starr, Angeles Alvarez Secord, Alexander B. Sibley, Herbert Hurwitz, Keiichi Fujiwara, Robert S. Mannel, Heidi J. Gray
Publikováno v:
Clin Cancer Res
Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demon